Abstracts Archive - Page 292 of 2607 - ACR Meeting Abstracts

Abstract Number: 1559 • ACR Convergence 2024
Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension
S. Ahmed¹, Eva Hoekstra², Katie van der Wouden², Sum-Che Man², Kees Swenne², Madelon Vonk³, Anna-Maria Hoffmann-Vold⁴, Cosimo Bruni⁵, Udo Mulder⁶, Thomas Huizinga⁷, H.W. Vliegen² and Jeska de Vries-Bouwstra², ¹Leiden University Medical Centre, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Oslo University Hospital, Oslo, Norway, ⁵University of Zurich, Zurich, Switzerland, ⁶Universitair Medisch Centrum Groningen, Groningen, Netherlands, ⁷Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: Pulmonary hypertension (PH) in SSc causes significant disease burden and requires invasive diagnosis with right heart catheterization (RHC). Comprehensive work-up is needed to identify…
Abstract Number: 1572 • ACR Convergence 2024
Associations Between the Gut Microbiota, Ultra-Processed Food Intake, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis
Ju Young Lee¹, Swapna Joshi², Arissa Young³, Jen Labus², Zsuzsanna McMahan⁴, Ezinne Aja², Jonathan Jacobs² and Elizabeth Volkmann⁵, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA, Los Angeles, CA, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles
Background/Purpose: Alterations in the gastrointestinal (GI) microbiome (i.e., dysbiosis) are a feature of systemic sclerosis (SSc) [1]. Diet is a known modifier of the GI…
Abstract Number: 0469 • ACR Convergence 2024
SCORE2 Is Superior to SCORE in Predicting the Presence of Carotid Plaques and Intima-media Thickness in Rheumatoid Arthritis Patients: A Cross-sectional Study with Carotid Ultrasound
Cristina Campos Fernández¹, Jorge Juan Fragío Gil², Roxana González Mazario³, Pablo Martínez Calabuig⁴, Laura Salvador Maicas⁵, Mireia Lucía Sanmartín Martínez⁶, Iván Jesús Lorente Betanzos⁶, Clara Molina Almela⁶, juan José Lerma Garrido⁷, Amalia Rueda³ and Jose A Román-Ivorra⁸, ¹Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ²Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, ³Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ⁴HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ⁵Consorcio Hospital General Universitario de Valencia, Castellón de la Plana, Comunidad Valenciana, Spain, ⁶Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁷Hospital General Universitario Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) escalates the risk of premature mortality, predominantly through cardiovascular diseases. Although SCORE and its updated version, SCORE2, are employed to assess…
Abstract Number: 1064 • ACR Convergence 2024
Inpatient and Outpatient Palliative Care Referral Practices for Patients with Rheumatic Disease: Retrospective Chart Review at a Single Academic Medical Center
Shannon Herndon¹, Jack Kimball¹ and David Leverenz², ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Palliative medicine prioritizes quality of life and relief of suffering in serious illness. Despite high morbidity and mortality in rheumatic disease, data suggests that…
Abstract Number: 1322 • ACR Convergence 2024
Maternal Antenatal Attachment in Women with Rheumatic Diseases
Maria Corral-Trujillo¹, Rodrigo Alfonso Cerda González², Luis C Berlanga-Muñoz³, Rodrigo Cantú-Barreda⁴, Brayan U Montes-Rodríguez⁵, Anahí Carrazco Chapa⁶, América M Burciaga Garza⁵, Jesus Cardenas-de la Garza¹, Lorena Perez-Barbosa⁷, CASSANDRA SKINNER TAYLOR⁸ and Dionicio Galarza-Delgado⁹, ¹Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ²Universidad Autónoma de Nuevo León, Santa Catarina, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Monterre, Mexico, ⁴Hospital Universitario, Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁶Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, ⁷Hospital Universitario, UANL, Monterrey, Mexico, ⁸HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, ⁹UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: The maternal antenatal attachment (MAA) is defined as the emotional bond between a pregnant woman and her unborn child. The quality of this relationship…
Abstract Number: 1587 • ACR Convergence 2024
Predictors of Body Mass Index in an Early Systemic Sclerosis Cohort
Ali Ayla¹, Meng Zhang¹, Claudia Pedroza², Bingrui Chen², Brian Skaug¹, Maureen Mayes¹, Shervin Assassi¹ and Zsuzsanna McMahan¹, ¹UTHealth Houston Division of Rheumatology, Houston, TX, ²UTHealth Houston, Houston, TX
Background/Purpose: Malnutrition is a significant problem among patients with systemic sclerosis (SSc). Body mass index (BMI) is often low in patients with malnutrition. Low BMI…
Abstract Number: 1536 • ACR Convergence 2024
Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties
JM JANSZ¹, EA Troy², WL Galanter³, Elaine Adams⁴, Nadera Sweiss⁵ and HJ CHANG⁶, ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois at Chicago, Woodridge, IL, ³University of Illinois at Chicago; Jesse Brown VA Medical Center, CHICAGO, IL, ⁴Jesse Brown VA Medical Center, La Grange, IL, ⁵University of IL, Chicago, IL, ⁶RHEUMATOLOGIST, CHICAGO, IL
Background/Purpose: Lupus nephritis is a well-known and severe complication in patients with systemic lupus erythematosus (SLE) that can lead to significant morbidity and mortality. Angiotensin-converting…
Abstract Number: 1568 • ACR Convergence 2024
Distribution of Proteinuria in Scleroderma Renal Crisis: A Multi-Center Study
Arifa Javed¹, Lilit Grigoryan², Alex Luta³, Sumbal Wajid², Lee Shapiro⁴, Virginia Steen⁵ and Swati Mehta⁶, ¹Albany Medical Center, Rensselaer, NY, ²Albany Medical Center, Albany, NY, ³MedStar Georgetown University Hospital, Rockville, MD, ⁴Albany Medical College, Stillwater, NY, ⁵Georgetown University School of Medicine, Washington, DC, ⁶Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is a rare but life-threatening complication of systemic sclerosis (SSc), characterized by malignant hypertension and acute kidney injury (AKI). Proteinuria when present at the time of…
Abstract Number: 1583 • ACR Convergence 2024
The Association of Weakpositive Anti-RNA Polymerase III Antibodies with the Diagnosis and Complications of Systemic Sclerosis and Other Systemic Autoimmune Diseases
Mashood Badshah¹, Warren Balaja², Brannon Donovan³, Paul Schmidt³ and Megan Krause⁴, ¹The University of Kansas Medical Center, Kansas City, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, ⁴University of Kansas, Kansas City, KS
Background/Purpose: Anti-RNA polymerase III antibody (ARA) is associated with systemic sclerosis (SSc). The presence of ARA in patients with SSc is associated with the risk…
Abstract Number: 1547 • ACR Convergence 2024
Hydroxychloroquine and Prednisone Use by Individuals Diagnosed with Systemic Lupus Erythematosus in the TriNetX Research Database
Moises Narvaez¹, Mujeeb Basit² and David Karp³, ¹UT Southwestern Medicial Center, Dallas, ²UT Southwestern Medical Center, Dallas, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: The current treatment guidelines for systemic lupus erythematosus emphasize the universal use of antimalarials such as hydroxychloroquine (HCQ) unless contraindicated as well as limited…
Abstract Number: 1453 • ACR Convergence 2024
Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection (XKH004) in Patients with Active Ankylosing Spondylitis: Findings from a 24-Week, Phase 2 Multicenter, Randomized, Placebo-Controlled Study
Ling Zhou¹, Juan Zhao¹, Lingyun Sun², Xuan Zhang³, Xiaomei Li⁴, Jiankang Hu⁵, Lijun Wu⁶, Zhenyu Jiang⁷, Min Yang⁸, Xiaoxia Wang⁹, Yongjun Mei¹⁰, Qingchun Huang¹¹, Yongtao Chen¹², Yang Li¹³, Lingli Dong¹⁴, Hui Luo¹⁵, Li Guo¹⁶, Jianguo You¹⁶, Yunpeng Zhang¹⁶, Ke Ren¹⁶ and Huji Xu¹, ¹Shanghai Changzheng Hospital, Shanghai, China (People's Republic), ²Nanjing Drum Tower Hospital, Nanjing, China (People's Republic), ³Beijing Hospital, Beijing, China, ⁴The First Affiliated Hospital of University of Science and Technology of China, Anhui, China (People's Republic), ⁵Department of Rheumatology, Pingxiang People's Hospital, Pingxiang, China, Pingxiang, China (People's Republic), ⁶People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China (People's Republic), ⁷The First Hospital of Jilin University, Changchun, China (People's Republic), ⁸Nanfang Hospital, Guangzhou, China (People's Republic), ⁹Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ¹⁰The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹¹The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic), ¹²West China Hospital, Sichuan University, Chengdu, China (People's Republic), ¹³Guangdong Provincial People's Hospital, Guangzhou, China (People's Republic), ¹⁴Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ¹⁵Xiangya Hospital, Central South University, Changsha, China (People's Republic), ¹⁶Kanova Biopharma, Zhejiang, China (People's Republic)
Background/Purpose: XKH004, the first recombinant anti-human IL-17A/F humanized monoclonal antibody in China (also known as XKH004), shares the same therapeutic target as Bimekizumab from UCB…
Abstract Number: 1579 • ACR Convergence 2024
Exploring the Cardiovascular Complications of Pulmonary Arterial Hypertension in Individuals with Systemic Sclerosis
Omar Mourad¹, Saif Abu Baker¹, Georges Khattar², Jennifer Jdaidani³, Khalil El-Gharib³ and Ahmad Mustafa³, ¹Staten Island University Hospital- Northwell Health, Staten Island, NY, ²Staten Island University Hospital, Staten Island, NY, ³Staten Island University Hospital- Northwell Health, Staten Island
Background/Purpose: Systemic sclerosis (SS) is a complex autoimmune rheumatic disease characterized by immune-mediated activation of both innate and adaptive immunity. Pulmonary involvement, specifically pulmonary arterial…
Abstract Number: 1581 • ACR Convergence 2024
Neutrophil-to- lymphocyte Ratio: A Possible Biomarker for Clinical Response After Autologous Hematopoietic Stem Cell Transplantation
shiri keret¹, Lisa Kaly², Georg Schett³, Christina Bergmann⁴, Joerg Henes⁵, Gleb Slobodin² and Doron Rimar², ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁴Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁵University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Baseline high Neutrophil- to- lymphocyte ratio (NLR) (higher than 2.95) is associated with severe progressive skin and lung disease and with reduced 5-year survival…
Abstract Number: 1549 • ACR Convergence 2024
Prescribing Trends for Novel Treatments in Systemic Lupus from 2017 to 2022
Celestine He¹, Zhonghan Li¹, Sumanth Chennareddy² and Chrisanna Dobrowolski³, ¹Icahn School of Medicine, Mount Sinai, New York, NY, ²Icahn School of Medicine, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Treatment of Systemic Lupus Erythematosus (SLE) has evolved substantially in the past decade. In 2011, the FDA approved belimumab, the first targeted monoclonal antibody…
Abstract Number: 1478 • ACR Convergence 2024
Associations Between Clinical Characteristics and Screening MRI Findings: Exploratory Analysis of the Ongoing Phase 4, Multicenter, Randomized, Controlled STAR Study of Biologic-Naïve Patients with PsA with MRI-Confirmed Axial Involvement
Xenofon Baraliakos¹, Paul Bird², Atul Deodhar³, Dafna Gladman⁴, Philip S. Helliwell⁵, Denis Poddubnyy⁶, Arthur Kavanaugh⁷, Mikkel Ostergaard⁸, Enrique R. Soriano⁹, Lai-shan Tam¹⁰, Soumya Chakravarty¹¹, Evan Leibowitz¹², Cinty Gong¹³, Stephen Xu¹⁴, Thomas Fuerst¹⁵, Nadeem Saeed¹⁶, Robert Landewé¹⁷ and Philip Mease¹⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²University of New South Wales, Randwick, NSW, Sydney, New South Wales, Australia, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁶Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁷University of California San Diego, La Jolla, CA, ⁸Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁰The Chinese University of Hong Kong, New Territories, Hong Kong, ¹¹Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, ¹²Janssen Scientific Affairs, LLC, Fair Lawn, NJ, ¹³Janssen Scientific Affairs, Horsham, PA, ¹⁴Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ¹⁵Clario, San Mateo, CA, ¹⁶Clario, San Mateo, ¹⁷Amsterdam University Medical Center, Meerssen, Netherlands, ¹⁸Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Patients (pts) with PsA can develop axial inflammation in the SI joints (SIJs) and/or spine. Although validated classification criteria for axial spondyloarthritis exist, established…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].